vs
Orthofix Medical Inc.（OFIX）与BRC Group Holdings, Inc.（RILY）财务数据对比。点击上方公司名可切换其他公司
Orthofix Medical Inc.的季度营收约是BRC Group Holdings, Inc.的1.2倍（$219.9M vs $188.3M），BRC Group Holdings, Inc.净利率更高（47.9% vs -1.0%，领先49.0%），Orthofix Medical Inc.同比增速更快（2.0% vs -21.9%），过去两年Orthofix Medical Inc.的营收复合增速更高（8.0% vs -15.4%）
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
OFIX vs RILY — 直观对比
营收规模更大
OFIX
是对方的1.2倍
$188.3M
营收增速更快
OFIX
高出23.8%
-21.9%
净利率更高
RILY
高出49.0%
-1.0%
两年增速更快
OFIX
近两年复合增速
-15.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $219.9M | $188.3M |
| 净利润 | $-2.2M | $90.3M |
| 毛利率 | 71.1% | 79.5% |
| 营业利润率 | 0.2% | 32.3% |
| 净利率 | -1.0% | 47.9% |
| 营收同比 | 2.0% | -21.9% |
| 净利润同比 | 92.4% | 1710.8% |
| 每股收益（稀释后） | $-0.05 | $2.78 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收OFIXRILY
| Q4 25 | $219.9M | $188.3M | ||
| Q3 25 | $205.6M | $215.3M | ||
| Q2 25 | $203.1M | $188.2M | ||
| Q1 25 | $193.6M | $197.2M | ||
| Q4 24 | $215.7M | $241.0M | ||
| Q3 24 | $196.6M | $225.5M | ||
| Q2 24 | $198.6M | $256.0M | ||
| Q1 24 | $188.6M | $263.4M |
净利润OFIXRILY
| Q4 25 | $-2.2M | $90.3M | ||
| Q3 25 | $-22.8M | $91.1M | ||
| Q2 25 | $-14.1M | $139.5M | ||
| Q1 25 | $-53.1M | $-10.0M | ||
| Q4 24 | $-29.1M | $-5.6M | ||
| Q3 24 | $-27.4M | $-284.4M | ||
| Q2 24 | $-33.4M | $-433.6M | ||
| Q1 24 | $-36.0M | $-49.2M |
毛利率OFIXRILY
| Q4 25 | 71.1% | 79.5% | ||
| Q3 25 | 72.2% | 83.7% | ||
| Q2 25 | 68.7% | 81.3% | ||
| Q1 25 | 62.8% | 81.4% | ||
| Q4 24 | 69.0% | 79.8% | ||
| Q3 24 | 68.7% | 82.1% | ||
| Q2 24 | 67.8% | 84.5% | ||
| Q1 24 | 67.5% | 85.3% |
营业利润率OFIXRILY
| Q4 25 | 0.2% | 32.3% | ||
| Q3 25 | -8.3% | 30.4% | ||
| Q2 25 | -7.9% | 5.7% | ||
| Q1 25 | -25.2% | -31.2% | ||
| Q4 24 | -5.3% | -69.2% | ||
| Q3 24 | -9.6% | -36.4% | ||
| Q2 24 | -12.5% | -90.8% | ||
| Q1 24 | -15.6% | -6.1% |
净利率OFIXRILY
| Q4 25 | -1.0% | 47.9% | ||
| Q3 25 | -11.1% | 42.3% | ||
| Q2 25 | -6.9% | 74.1% | ||
| Q1 25 | -27.4% | -5.1% | ||
| Q4 24 | -13.5% | -2.3% | ||
| Q3 24 | -13.9% | -126.1% | ||
| Q2 24 | -16.8% | -169.4% | ||
| Q1 24 | -19.1% | -18.7% |
每股收益（稀释后）OFIXRILY
| Q4 25 | $-0.05 | $2.78 | ||
| Q3 25 | $-0.57 | $2.91 | ||
| Q2 25 | $-0.36 | $4.50 | ||
| Q1 25 | $-1.35 | $-0.39 | ||
| Q4 24 | $-0.76 | $-0.01 | ||
| Q3 24 | $-0.71 | $-9.39 | ||
| Q2 24 | $-0.88 | $-14.35 | ||
| Q1 24 | $-0.95 | $-1.71 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $82.0M | $226.6M |
| 总债务越低越好 | — | $1.4B |
| 股东权益账面价值 | $450.0M | $-171.5M |
| 总资产 | $850.6M | $1.7B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资OFIXRILY
| Q4 25 | $82.0M | $226.6M | ||
| Q3 25 | $62.9M | $184.2M | ||
| Q2 25 | $65.6M | $267.4M | ||
| Q1 25 | $58.0M | $138.3M | ||
| Q4 24 | $83.2M | $146.9M | ||
| Q3 24 | $30.1M | $159.2M | ||
| Q2 24 | $26.4M | $236.9M | ||
| Q1 24 | $27.0M | $190.7M |
总债务OFIXRILY
| Q4 25 | — | $1.4B | ||
| Q3 25 | $157.2M | $1.3B | ||
| Q2 25 | $157.0M | $1.3B | ||
| Q1 25 | $156.9M | $1.4B | ||
| Q4 24 | $157.0M | $1.5B | ||
| Q3 24 | $118.5M | — | ||
| Q2 24 | $118.0M | — | ||
| Q1 24 | $118.2M | — |
股东权益OFIXRILY
| Q4 25 | $450.0M | $-171.5M | ||
| Q3 25 | $442.5M | $-260.5M | ||
| Q2 25 | $458.3M | $-351.7M | ||
| Q1 25 | $458.3M | $-496.8M | ||
| Q4 24 | $503.1M | $-488.2M | ||
| Q3 24 | $525.9M | $-497.6M | ||
| Q2 24 | $546.0M | $-218.3M | ||
| Q1 24 | $570.3M | $228.4M |
总资产OFIXRILY
| Q4 25 | $850.6M | $1.7B | ||
| Q3 25 | $832.6M | $1.7B | ||
| Q2 25 | $837.2M | $1.5B | ||
| Q1 25 | $823.1M | $1.5B | ||
| Q4 24 | $893.3M | $1.8B | ||
| Q3 24 | $867.9M | $2.2B | ||
| Q2 24 | $882.0M | $3.2B | ||
| Q1 24 | $906.0M | $5.0B |
负债/权益比OFIXRILY
| Q4 25 | — | — | ||
| Q3 25 | 0.36× | — | ||
| Q2 25 | 0.34× | — | ||
| Q1 25 | 0.34× | — | ||
| Q4 24 | 0.31× | — | ||
| Q3 24 | 0.23× | — | ||
| Q2 24 | 0.22× | — | ||
| Q1 24 | 0.21× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $27.7M | $26.2M |
| 自由现金流经营现金流 - 资本支出 | $16.8M | — |
| 自由现金流率自由现金流/营收 | 7.6% | — |
| 资本支出强度资本支出/营收 | 4.9% | — |
| 现金转化率经营现金流/净利润 | — | 0.29× |
| 过去12个月自由现金流最近4个季度 | $-1.3M | — |
8季度趋势，按日历期对齐
经营现金流OFIXRILY
| Q4 25 | $27.7M | $26.2M | ||
| Q3 25 | $12.4M | $-60.6M | ||
| Q2 25 | $11.6M | $-25.6M | ||
| Q1 25 | $-18.4M | $184.0K | ||
| Q4 24 | $23.7M | $-2.7M | ||
| Q3 24 | $11.7M | $19.5M | ||
| Q2 24 | $9.0M | $111.5M | ||
| Q1 24 | $-18.6M | $135.4M |
自由现金流OFIXRILY
| Q4 25 | $16.8M | — | ||
| Q3 25 | $2.5M | — | ||
| Q2 25 | $4.5M | — | ||
| Q1 25 | $-25.1M | — | ||
| Q4 24 | $15.2M | — | ||
| Q3 24 | $6.3M | — | ||
| Q2 24 | $-360.0K | — | ||
| Q1 24 | $-29.1M | — |
自由现金流率OFIXRILY
| Q4 25 | 7.6% | — | ||
| Q3 25 | 1.2% | — | ||
| Q2 25 | 2.2% | — | ||
| Q1 25 | -13.0% | — | ||
| Q4 24 | 7.0% | — | ||
| Q3 24 | 3.2% | — | ||
| Q2 24 | -0.2% | — | ||
| Q1 24 | -15.4% | — |
资本支出强度OFIXRILY
| Q4 25 | 4.9% | — | ||
| Q3 25 | 4.8% | — | ||
| Q2 25 | 3.5% | — | ||
| Q1 25 | 3.5% | — | ||
| Q4 24 | 4.0% | — | ||
| Q3 24 | 2.7% | — | ||
| Q2 24 | 4.7% | — | ||
| Q1 24 | 5.6% | — |
现金转化率OFIXRILY
| Q4 25 | — | 0.29× | ||
| Q3 25 | — | -0.66× | ||
| Q2 25 | — | -0.18× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
RILY
| Transferred At Point In Time | $101.4M | 54% |
| Wealth Management Segment | $30.7M | 16% |
| Corporate Finance Consulting And Investment Banking Fees | $27.1M | 14% |
| Services And Fees | $24.8M | 13% |
| Commissions Fees And Reimbursed Expenses | $4.8M | 3% |
